Natural killer cell immune escape in acute myeloid leukemia. (Q37996816)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22446501%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

title

Natural killer cell immune escape in acute myeloid leukemia (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22446501%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

1 reference

evasion of host immune response

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22446501%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

Zwi N Berneman

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22446501%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

Evelien Smits

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22446501%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

author name string

Y Willemen

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22446501%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

V F I Van Tendeloo

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22446501%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

publication date

26 March 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22446501%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22446501%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

volume

26

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22446501%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

issue

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22446501%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

page(s)

2019-2026

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22446501%20AND%20SRC:MED&resulttype=core&format=json

Immunotherapy of acute myeloid leukemia: current approaches.

26 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.87

Clinical evaluation of cellular immunotherapy in acute myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.87

Close encounters of different kinds: dendritic cells and NK cells take centre stage

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.87

Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.87

Natural killer cell alloreactivity in allogeneic hematopoietic transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.87

Use of natural killer cells in hematopoetic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.87

HLA and KIR polymorphisms affect NK-cell anti-tumor activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.87

Role of natural killer cells in hematopoietic stem cell transplantation: myth or reality?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.87

NK cell-mediated targeting of human cancer and possibilities for new means of immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.87

Natural killer cell-directed therapies: moving from unexpected results to successful strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.87

The difference in NK-cell activity between patients with non-Hodgkin's lymphomas and Hodgkin's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.87

Reduced natural killer (NK) function associated with high-risk myelodysplastic syndrome (MDS) and reduced expression of activating NK receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.87

Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.87

Immunotherapy for myeloid leukemias: current status and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.87

Natural killer cell function and lymphoid subpopulations in acute non-lymphoblastic leukaemia in complete remission

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.87

The in vitro detection of anti-leukaemia-specific cytotoxicity after autologous bone marrow transplantation for acute leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.87

Synergy among receptors on resting NK cells for the activation of natural cytotoxicity and cytokine secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.87

Defective expression and function of natural killer cell-triggering receptors in patients with acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.87

Deficient expression of NCR in NK cells from acute myeloid leukemia: Evolution during leukemia treatment and impact of leukemia cells in NCRdull phenotype induction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.87

Interleukin-15 enhances natural killer cell cytotoxicity in patients with acute myeloid leukemia by upregulating the activating NK cell receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.87

Human NK cells in acute myeloid leukaemia patients: analysis of NK cell-activating receptors and their ligands

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.87

Analysis of the receptor-ligand interactions in the natural killer-mediated lysis of freshly isolated myeloid or lymphoblastic leukemias: evidence for the involvement of the Poliovirus receptor (CD155) and Nectin-2 (CD112)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.87

Identification of natural killer cell receptor phenotypes associated with leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.87

Exploitation of alloreactive NK cells in adoptive immunotherapy of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.87

Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.87

Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.87

The beneficial role of inhibitory KIR genes of HLA class I NK epitopes in haploidentically mismatched stem cell allografts may be masked by residual donor-alloreactive T cells causing GVHD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.87

Role of KIR ligand incompatibility in hematopoietic stem cell transplantation using unrelated donors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.87

The effect of KIR ligand incompatibility on the outcome of unrelated donor transplantation: a report from the center for international blood and marrow transplant research, the European blood and marrow transplant registry, and the Dutch registry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.87

NK cell receptors and their ligands in leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.87

NK-cell reconstitution after haploidentical hematopoietic stem-cell transplantations: immaturity of NK cells and inhibitory effect of NKG2A override GvL effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.87

Ligands for natural killer cell-activating receptors are expressed upon the maturation of normal myelomonocytic cells but at low levels in acute myeloid leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.87

Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.87

NKG2D ligand expression in AML increases in response to HDAC inhibitor valproic acid and contributes to allorecognition by NK-cell lines with single KIR-HLA class I specificities

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.87

Glucocorticoid-induced tumor necrosis factor receptor-related protein ligand subverts immunosurveillance of acute myeloid leukemia in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.87

CD137 ligand mediates opposite effects in human and mouse NK cells and impairs NK-cell reactivity against human acute myeloid leukemia cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.87

CD200 expression suppresses natural killer cell function and directly inhibits patient anti-tumor response in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.87

Soluble interleukin-2 receptor, soluble CD8 and soluble intercellular adhesion molecule-1 levels in hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.87

Deregulation of the mitochondrial apoptotic machinery and development of molecular targeted drugs in acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.87

Expression profile and specific network features of the apoptotic machinery explain relapse of acute myeloid leukemia after chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.87

Prognostic significance of Fas (CD95) and TRAIL receptors (DR4/DR5) expression in acute myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.87

Absence or low expression of fas-associated protein with death domain in acute myeloid leukemia cells predicts resistance to chemotherapy and poor outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.87

High TRAIL-R3 expression on leukemic blasts is associated with poor outcome and induces apoptosis-resistance which can be overcome by targeting TRAIL-R2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.87

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.87

Immature NK cells suppress dendritic cell functions during the development of leukemia in a mouse model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.87

Increased frequency and suppression by regulatory T cells in patients with acute myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.87

CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.87

CD4+CD25+ T regulatory cells suppress NK cell-mediated immunotherapy of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.87

Suppression of natural killer cell-mediated bone marrow cell rejection by CD4+CD25+ regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.87

Regulatory T cells in acute myelogenous leukemia: is it time for immunomodulation?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.87

Combination therapy using IL-2 and anti-CD25 results in augmented natural killer cell-mediated antitumor responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.87

Combination of imatinib mesylate with autologous leukocyte-derived heat shock protein and chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.87

Natural killer cell IFN-gamma levels predict long-term survival with imatinib mesylate therapy in gastrointestinal stromal tumor-bearing patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.87

Human natural killer cells undergoing in vivo differentiation after allogeneic bone marrow transplantation: analysis of the surface expression and function of activating NK receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.87

Reconstitution of natural killer cell receptors influences natural killer activity and relapse rate after haploidentical transplantation of T- and B-cell depleted grafts in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.87

Activated natural killer cells from patients with acute myeloid leukemia are cytotoxic against autologous leukemic blasts in NOD/SCID mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.87

CD56bright natural killer (NK) cells: an important NK cell subset.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.87

NK-cell-mediated killing of target cells triggers robust antigen-specific T-cell-mediated and humoral responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.87

NKG2D ligands in tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.87

NK cells and cancer immunosurveillance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.87

Interferon-α in acute myeloid leukemia: an old drug revisited

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.87

UL16-binding proteins, novel MHC class I-related proteins, bind to NKG2D and activate multiple signaling pathways in primary NK cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.87

Opposing effect of IFNgamma and IFNalpha on expression of NKG2 receptors: negative regulation of IFNgamma on NK cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.87

The role of the NKG2D receptor for tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.87

Novel aspects of in vitro IL-2 or IFN-α enhanced NK cytotoxicity of healthy individuals based on NKG2D and CD161 NK cell receptor induction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.87

Autologous immune strategies to reduce the risk of leukemic relapse: consideration for IL-15.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.87

Transforming growth factor beta 1 inhibits expression of NKp30 and NKG2D receptors: consequences for the NK-mediated killing of dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.87

Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.87

Natural killer cell allorecognition of missing self in allogeneic hematopoietic transplantation: a tool for immunotherapy of leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.87

Immunogenic and tolerogenic cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.87

Human acute myeloid leukemia CD34+CD38- stem cells are susceptible to allorecognition and lysis by single KIR-expressing natural killer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.87

NKG2D ligands: key targets of the immune response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.87

Differentiation-promoting drugs up-regulate NKG2D ligand expression and enhance the susceptibility of acute myeloid leukemia cells to natural killer cell-mediated lysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.87

Effective in vivo induction of NKG2D ligands in acute myeloid leukaemias by all-trans-retinoic acid or sodium valproate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.87

Altered NKG2D function in NK cells induced by chronic exposure to NKG2D ligand-expressing tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.87

Sustained localized expression of ligand for the activating NKG2D receptor impairs natural cytotoxicity in vivo and reduces tumor immunosurveillance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.87

Bortezomib and depsipeptide sensitize tumors to tumor necrosis factor-related apoptosis-inducing ligand: a novel method to potentiate natural killer cell tumor cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.87

Sensitization of tumor cells to NK cell-mediated killing by proteasome inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.87

Acute myeloid leukaemia cells secrete a soluble factor that inhibits T and NK cell proliferation but not cytolytic function--implications for the adoptive immunotherapy of leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.87

Increased population of CD4(+)CD25(high), regulatory T cells with their higher apoptotic and proliferating status in peripheral blood of acute myeloid leukemia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.87

Early evaluation of natural killer activity in post-transplant acute myeloid leukemia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.87

Natural killer cell activity of peripheral blood and bone marrow mononuclear cells from patients with childhood acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.87

7 January 2021

Loss of natural killer activity as an indicator of relapse in acute leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.87

7 January 2021

Evidence that continued remission in patients treated for acute leukaemia is dependent upon autologous natural killer cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.87

7 January 2021

Increased Infection-Related Mortality in KIR-Ligand???Mismatched Unrelated Allogeneic Hematopoietic Stem-Cell Transplantation

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.87

7 January 2021

Genotypic inhibitory killer immunoglobulin-like receptor ligand incompatibility enhances the long-term antileukemic effect of unmodified allogeneic hematopoietic stem cell transplantation in patients with myeloid leukemias

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.87

7 January 2021

Low number of donor activating killer immunoglobulin-like receptors (KIR) genes but not KIR-ligand mismatch prevents relapse and improves disease-free survival in leukemia patients after in vivo T-cell depleted unrelated stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.87

7 January 2021

HLA-E upregulation on IFN-γ-activated AML blasts impairs CD94/NKG2A-dependent NK cytolysis after haplo-mismatched hematopoietic SCT

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.87

7 January 2021

Production of tumour-derived suppressor factor in patients with acute myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.87

7 January 2021

Defective killing of dendritic cells by autologous natural killer cells from acute myeloid leukemia patients

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.87

7 January 2021

Elevated frequencies of CD4⁺ CD25⁺ CD127lo regulatory T cells is associated to poor prognosis in patients with acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.87

7 January 2021

Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.87

7 January 2021

Rapid natural killer cell recovery determines outcome after T-cell-depleted HLA-identical stem cell transplantation in patients with myeloid leukemias but not with acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.87

7 January 2021

Pre-eminence and persistence of immature natural killer cells in acute myeloid leukemia patients in first complete remission

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.87

7 January 2021

Induction of complete remission of acute myeloid leukaemia by pegylated interferon-alpha-2a in a patient with transformed primary myelofibrosis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.87

7 January 2021

Increased frequencies of T helper type 17 cells in the peripheral blood of patients with acute myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.87

7 January 2021

Up-regulation of NKG2D ligands by AML cells to increase sensitivity to NK cells: the tumour might strike back. Comment on "differentiation-promoting drugs up-regulate NKG2D ligand expression and enhance the susceptibility of acute myeloid leukemia c

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.87

7 January 2021

NK cells: key to success of DC-based cancer vaccines?

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.87

7 January 2021

Identifiers

DOI

10.1038/LEU.2012.87

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22446501%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

1 reference